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A B S T R A C T
Background: Alzheimer's disease (AD) is the most common neurodegenerative disorder. Depositions of amyloid β
peptide (Aβ) and tau protein are among the major pathological hallmarks of AD. Aβ and tau burden follows
predictable spatial patterns during the progression of AD. Nevertheless, it remains obscure why certain brain
regions are more vulnerable than others; to investigate this and dysregulated pathways during AD progression, a
mass spectrometry-based proteomics study was performed.
Methods: In total 103 tissue samples from regions early (entorhinal and parahippocampal cortices - medial
temporal lobe (MTL)) and late affected (temporal and frontal cortices - neocortex) by tau pathology were
subjected to label-free quantitative proteomics analysis.
Results: Considering dysregulated proteins during AD progression, the majority (625 out of 737 proteins) was
region specific, while some proteins were shared between regions (101 proteins altered in two areas and 11
proteins altered in three areas). Analogously, many dysregulated pathways during disease progression were
exclusive to certain regions, but a few pathways altered in two or more areas. Changes in protein expression
indicate that synapse loss occurred in all analyzed regions, while translation dysregulation was preponderant in
entorhinal, parahippocampal and frontal cortices. Oxidative phosphorylation impairment was prominent in
MTL. Differential proteomic analysis of brain areas in health state (controls) showed higher metabolism and
increased expression of AD-related proteins in the MTL compared to the neocortex. In addition, several proteins
that differentiate brain regions in control tissue were dysregulated in AD.
Conclusions: This work provides the comparison of proteomic changes in brain regions affected by tau pathology
at different stages of AD. Although we identified commonly regulated proteins and pathways during disease
advancement, we found that the dysregulated processes are predominantly region specific. In addition, a distinct
proteomic signature was found between MTL and neocortex in healthy subjects that might be related to AD
https://doi.org/10.1016/j.nbd.2019.104509
Received 27 December 2018; Received in revised form 17 May 2019
Abbreviations: AD, Alzheimer's disease; EC, Entorhinal cortex; PHC, Parahippocampal cortex; TC, Temporal cortex; FC, Frontal cortex; MTL, Medial temporal lobe;
NFT, Neurofibrillary tangles; Aβ, Amyloid β peptide; CBD, Corticobasal degeneration; PSP, Progressive supranuclear palsy; DEP, Differentially expressed protein;
AMBIC, Ammonium-bicarbonate; DTT, Dithiothreitol; IAA, Iodoacetamide; TFA, Trifluoroacetic acid
⁎ Corresponding authors at: Gilberto B. Domont, Proteomics Unit, Department of Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; Melinda
Rezeli, Division of Clinical Protein Science & Imaging, Department of Clinical Sciences (Lund) and Department of Biomedical Engineering, Lund University, Lund,
Sweden.
E-mail addresses: gilbertodomont@gmail.com (G.B. Domont), melinda.rezeli@bme.lth.se (M. Rezeli).
Neurobiology of Disease 130 (2019) 104509
Available online 15 June 2019
0969-9961/ © 2019 Elsevier Inc. All rights reserved.
T
Downloaded for Anonymous User (n/a) at University of Szeged from ClinicalKey.com by Elsevier on June 25, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
vulnerability. These findings highlight the need for investigating AD's cascade of events throughout the whole
brain and studies spanning more brain areas are required to better understand AD etiology and region vulner-
ability to disease.
1. Introduction
Alzheimer's disease (AD) is the most prevalent neurodegenerative
disorder and also the major cause of dementia (60–80% cases)
(Alzheimer's Association, A. S, 2017). Major hallmarks of AD are loss of
synapses, neuronal death and deposition of extracellular amyloid β
peptide (Aβ) and intracellular hyperphosphorylated tau protein
(Masters et al., 2015). During AD progression Aβ and tau aggregates
spread through the brain, following predictable patterns (Braak and
Braak, 1991; Thal et al., 2002). Tau deposition was classified into six
neuropathological stages designated as Braak/Braak (B/B) stages
(Braak and Braak, 1991). During B/B I-II, tau inclusions are restricted to
the transentorhinal and entorhinal cortices. They disseminate into the
limbic system during B/B III-IV with the mild engagement of the hip-
pocampus (CA1–4), parts of the frontal and temporal neocortices and
the amygdala. The final stages, B/B V-VI, are distinguished by the de-
struction of the neocortex by protein inclusions (Hyman et al., 2012).
There is a correlation between cognitive impairment and the number of
neuritic plaques (Aβ plaques) in the neocortex, but cortical tau neuro-
fibrillary tangles (NFT) burden correlates better with cognitive decline
(Nelson et al., 2007).
Since AD progressively affects distinct brain regions, many studies
compared the changes that occur in different regions, trying to eluci-
date which processes make an area more vulnerable than another one
(Martin et al., 2008; Schonberger et al., 2001; Xu et al., 2019; Zahid
et al., 2014). Other authors focused on the temporal advancement of AD
by investigating changes that occur in one brain area at different dis-
ease stages (Bossers et al., 2010; Hondius et al., 2016; Kim et al., 2018;
Lachén-Montes et al., 2017; Lau et al., 2013; Sultana et al., 2010;
Triplett et al., 2016; Zelaya et al., 2015). Both strategies were also
merged through transcriptomic/proteomic investigation of brain areas
considering distinct disease stages (Matarin et al., 2015; McKetney
et al., 2019; Miyashita et al., 2014; Savas et al., 2017; Seyfried et al.,
2017).
Although many works have profiled molecular alterations in the AD
brain, a large human study investigating proteomic changes at different
B/B stages in brain areas vulnerable and resilient to tau pathology is
still lacking. With the aim to map proteome dysregulation during AD
progression in brain regions with distinct susceptibility to neurode-
generation and to investigate which processes make some brain areas
more vulnerable to AD, we performed quantitative proteome profiling
of 103 human brain samples from regions affected by tau pathology
already in the early (medial temporal lobe (MTL)) or only the late
stages of AD (neocortex).
2. Methods
2.1. Patient cohort
A total of 103 postmortem human brain samples from 4 distinct
brain regions (entorhinal cortex (Brodmann areas 28 and 34), para-
hippocampal cortex (posterior two thirds of the parahippocampal
gyrus), temporal cortex (Brodmann area 21) and frontal cortex
(Brodmann area 10)) were acquired from the Human Brain Tissue Bank
(Semmelweis University, Budapest, Hungary). All brains were diag-
nosed by a neuropathologist according to the standard diagnostic cri-
teria as described previously (Skogseth et al., 2017). In brief, the neu-
ropathological diagnosis of AD was established when AD-type tau
pathology was present in forms of neurofibrillary tangles, neuropil
threads and Alzheimer's type (neuritic) plaques with coexisting
characteristic amyloid beta pathology. The probability of AD is based
on tau Braak & Braak (B/B) stage. Pure AD cases have been selected, i.e.
brains without significant coexisting non-AD pathologies such as FTLD-
tau, PSP, CBD. Cases were classified according to tau pathology (B/B
stages) into controls (negative or minimal age-related tau pathology)
and B/B stages (I, II, III, IV, V and VI) (Table S1). The work has been
carried out in accordance with the Declaration of Helsinki. Brains were
donated under informed written consent.
2.2. Microdissection procedure
After dissecting the whole brain from the skull, the leptomeninges
were first removed from the surface of the brain. Subsequently, the
cortex with the diencephalon was separated from the lower brainstem/
cerebellum by a knife cut through the midbrain. Then, the cortex was
sliced at the coronal level from the frontal pole with 1.5–2.0 cm thick
sections. Each section (generally 11–12 from the whole brain) was
immediately frozen individually on dry ice powder, covered in alu-
minum foil and stored at −70 °C. During the microdissection of the
cortical samples, each frozen coronal section was further cut into
1–2mm thin sections and the cortical areas were dissected out by the
“micropunch technique” (Palkovits, 1973) using special micropunch
needles with various (0.5–3.0mm) inside diameters according to the
size of the cortical areas or regions to be dissected. The microdissected
tissue pellets were collected in 1.5ml Eppendorf tubes and kept until
use at −70 °C. During each step of the microdissection procedure, the
brain slices and samples were kept frozen. For the present study, sam-
ples were taken from the entorhinal and parahippocampal cortex, the
temporal cortex represented by micropunches from the middle tem-
poral gyrus, and the frontal cortex by samples from the superior frontal
gyrus.
2.3. Reagents
All reagents used were acquired from Sigma-Aldrich unless speci-
fied. Organic solvents and water with LC-MS quality were bought from
Merck.
2.4. Protein extraction and digestion
The microdissected frozen tissue samples were sectioned at −20 °C
using a cryostat to obtain 10 μm slices (20–60 slices per sample) and
samples were stored at −80 °C until further usage. 200 μL of lysis buffer
(7M urea, 2M thiourea, 50mM Tris pH 7.4, MS-SAFE protease in-
hibitor) was added to each microcentrifuge tube containing the tissue
slices. Samples were vortexed and then sonicated on ice (Digital
Branson Sonicator SFX 150): 20% amplitude, pulsed mode (9 pulses
with 10 s each and intervals of 10 s between each pulse). Lysates were
centrifuged at 21,000 xg at 4 °C for 30min (Eppendorf Nordic A/S) and
the supernatant was transferred to a new tube to avoid cell debris. Prior
to digestion, protein quantification was done using the Bradford 96 well
plate assay, according to the manufacturer instructions.
Protein digestion was carried out using a modified Filter Aided
Sample Preparation (FASP) protocol (Wisniewski et al., 2009). 100 μg
protein was used for digestion. Reduction of disulfide bonds was per-
formed by the addition of 50mM dithiothreitol (DTT) to the lysates that
were then incubated for 1 h at 30 °C. The samples were then transferred
to 30 kDa Microcon filters (Merck Millipore) connected to collection
tubes. 200 μL of U/Tris buffer (8M Urea in 0.1M Tris-HCl pH 8.5) was
added and the filter units were centrifuged at 12,000 xg for 15min at
C.F. Mendonça, et al. Neurobiology of Disease 130 (2019) 104509
2
Downloaded for Anonymous User (n/a) at University of Szeged from ClinicalKey.com by Elsevier on June 25, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
room temperature. For alkylation of the cysteine residues, 50 μL of
50mM iodoacetamide (IAA) in U/Tris buffer was added to the samples
and the reaction was incubated in dark for 20min at room temperature.
IAA was then removed from the samples by filtration at 12,000 x g for
15min. After that, 100 μL of U/Tris buffer was added to the filters and
another centrifugation step with the same conditions was carried out.
Prior to digestion U/Tris buffer was replaced to ammonium bicarbonate
buffer (AMBIC) by the addition of 100 μL of 50mM AMBIC, followed by
centrifugation 12,000 xg for 15min. This step was repeated 4 times.
Filters containing the proteins were transferred to new collection tubes
and 50 μL of 0.04 μg/uL sequencing grade modified trypsin (1:50 en-
zyme: protein ratio, Promega Biotech AB, Madison, WI) in AMBIC was
added to each sample. Following overnight digestion at 37 °C, the
peptides were collected by centrifugation at 12,000 xg for 15min. Two
elution steps were carried out by the addition of 100 uL of AMBIC,
followed by centrifugation. Formic acid was added to a final con-
centration of 0.5%. Peptides were dried with speed vacuum cen-
trifugation, then resuspended in 100 μL of 0.1% trifluoroacetic acid
(TFA) and finally desalted by reversed phase chromatography using
C18 spin columns (MacroSpin Columns®, The Nest Group Inc.). After
desalting, tryptic peptides were dried and resuspended in 50 μL of 0.1%
formic acid. Prior to injection onto the mass spectrometer, peptides
were quantified using the Pierce Quantitative Colorimetric Peptide
Assay (Thermo Fisher Scientific, Rockford, lL).
2.5. Liquid chromatography coupled to tandem mass spectrometry (LC-MS/
MS)
1 μg of the tryptic peptides was injected for each analysis spiked
with the Pierce retention time calibration mixture (PRTC) (Thermo
Fisher Scientific, Rockford, lL) (25 fmol/injection). For LC-MS/MS
analysis, we used a Thermo Q Exactive mass spectrometer (Thermo
Scientific, Waltham, MA) equipped with a Dream ionization source
(AMR Inc., Tokyo) and connected to an Easy n-LC 1000 liquid chro-
matography system (Thermo Scientific, Waltham, MA). Peptides were
injected on an Acclaim PepMap 100 pre-column (100 μm×2 cm,
Thermo Fisher Scientific) and separated on a Zaplous α Pep-C18 ana-
lytical column (0.1mm×20 cm, AMR Inc., Tokyo) at a flow rate of
500 nL/min and a column temperature at 24 °C. A non-linear gradient
was established using solvents A (0.1% formic acid in water) and B
(0.1% formic acid in acetonitrile) to elute the peptides. The gradient
started with 5% solvent B and increased to 22% during 100min. In the
next 14min, solvent B increased to 32% and finally, it augmented to
95% in 12min and it was kept at 95% for 14min. Samples were ana-
lyzed using a top 15 data-dependent acquisition (DDA) method. MS1
scan was acquired in the Orbitrap analyzer with a 400–1600m/z in-
terval, 70,000 (@ 200m/z) resolution, target AGC value of 1e6 and
maximum injection time of 100ms. The 15 most intense peaks (charge
≥2) were selected and fragmented in a Higher Energy Collisional
Dissociation (HCD) cell with a normalized collision energy of 30%. MS2
spectra were acquired with a 17,500 (@ 200m/z) resolution, target
AGC value of 2e5 and maximum injection time of 120ms. The ion se-
lection threshold was set to 8.3e3 and dynamic exclusion was set to
20 s. Samples were randomly analyzed and each run was followed by a
blank injection (0.1% formic acid in MilliQ water) with a short gradient
of 35min to avoid any residues from the previous sample. A quality
control sample (QC) was prepared from a pool of 4 brain digests spiked
with PRTC. 1 μg of QC sample together with 25 fmoles of PRTC peptides
was injected after every 15 samples in order to evaluate system stabi-
lity.
2.6. Protein inference and relative quantification
Raw data generated on the mass spectrometer was analyzed using
the software Proteome Discoverer (PD) version 2.1 (Thermo Scientific,
Waltham, MA). Peptide identification was done with the SEQUEST HT
algorithm using the UniProt human database as reference (version from
07/09/2016, canonical sequences only). The following search para-
meters were employed: cysteine carbamidomethylation as static mod-
ification, methionine oxidation as dynamic modification, 10 ppm tol-
erance for precursor ions and 0.02 Da for fragment ions. A maximum of
2 missed cleavages was allowed. Protein quantification was done using
the Precursor Ions Area Detector node, where the average of the 3 most
intense peptides was used for protein quantification, being considered
only unique peptides. The mass spectrometry proteomics data have
been deposited to the ProteomeXchange Consortium via the PRIDE
(Vizcaíno et al., 2015) partner repository with the dataset identifier
PXD010138.
2.7. Targeted MS/MS analysis by parallel reaction monitoring (PRM)
Parallel reaction monitoring (PRM) was employed to verify a set of
differentially expressed proteins. One to five unique peptides for each
protein of interest were selected, and in the final assay, 75 peptides
corresponding to 21 proteins (including apolipoprotein E2, E3, and E4
and a peptide associated with Aβ) were monitored (Table S2). The
protein digests were spiked with a mixture of stable isotope standard
peptides (SIS) correspond to apolipoprotein E (4 isoform-specific pep-
tides and one peptide that is common in all isoforms). 1 μg of the tryptic
peptides was injected for each analysis spiked with SIS peptides (20
fmoles/injection). For the PRM analysis, a Thermo Q Exactive HF-X
mass spectrometer was used equipped with an Easy-spray source and
connected to an UltiMate 3000 RSLCnano system (Thermo Scientific,
Waltham, MA). Peptides were injected on an Acclaim PepMap 100 pre-
column (75 μm×2 cm, C18, 3mm, 100 Å Thermo Scientific) and se-
parated on an EASY-Spray column (75 μm×25 cm, PepMap RSLC C18,
2mm, 100 Å) at a flow rate of 300 nL/min and a column temperature at
45 °C. A non-linear gradient was established using solvents A (0.1%
formic acid in water) and B (0.1% formic acid in 80% acetonitrile) to
elute the peptides. The gradient started with 4% solvent B and in-
creased to 30% in 30min. In the next 5min, solvent B increased to 45%
and finally increased to 98% in 1min and it was kept at 98% for 5min.
Targeted MS2 mode was operated with the time-scheduled acqui-
sition of the selected precursors with 3min retention time windows.
MS2 scans were acquired using 30,000 (@ 200m/z) resolution, the AGC
target value was set to 2e5 and 100ms maximum injection time was
used. Fragmentation was performed with a normalized collision energy
of 27. Samples were randomly analyzed, and each run was followed by
a blank injection to avoid any residues from the previous sample.
2.8. Bioinformatics and statistical analysis
Proteins identified from database search that fulfilled the following
requirements were subjected to further analysis: master protein, 1%
FDR, and identified with at least 2 peptides. Statistical analysis was
carried out in Perseus v 1.6.0.7 and R. Protein area values were con-
verted to log2 scale and normalized by subtracting the median of the
sample distribution. Proteins with<50% valid values in each group
(controls, early and late B/B) were removed from the analysis. The
remaining proteins were subjected to missing value imputation using
the default parameters (width 0.3, down shift 1.8) of the Perseus im-
putation tool. Sex, age and post mortem intervals were compared be-
tween the three groups (control, early and late B/B stages) in each re-
gion using Chi-square test (for binary data) and linear regression (for
continuous numerical values) to determine whether these variables
differ between groups. These tests showed that the disease groups were
unbalanced with respect to age (p-value< 0.0338) and sex (p-
value< 0.1551) in the four brain regions (Fig. S1). Accordingly, all
proteins significantly associated with age or sex (linear regression
analysis, p-value<0.05) were removed from the list of differentially
expressed proteins. In order to evaluate differentially expressed pro-
teins (DEPs) during disease progression, Student's t-test was applied to
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compare early B/B (I-III) and late B/B (IV-VI) stages with the control
group (p-value<0.05, fold change ≤0.66 or≥ 1.5) in each brain re-
gion. Analysis of DEPs between the 4 brain regions in health state was
performed using one-way ANOVA with post-hoc Tukey's honestly sig-
nificant difference (HSD) test. The following requirements were used to
determine significance: adjusted p-value< 0.05 and fold change ≤0.66
or≥ 1.5. Heat maps were generated from hierarchical clustering based
on average Euclidean distance and complete linkage, using R.
Venn diagrams were generated with an online tool from Ghent
University (http://bioinformatics.psb.ugent.be/webtools/Venn/).
Protein-protein interaction networks were built with String version
10.5 (https://string-db.org/) using 0.7 as the minimum required in-
teraction score (high confidence). Gene ontology enrichment analysis
was carried out on String version 10.5 and DAVID version 6.8 (https://
david.ncifcrf.gov/).
Verification of DEPs identified in the present work was performed
by comparison with two other AD proteomic studies (Hondius et al.,
2016; Seyfried et al., 2017), and only proteins reported to be sig-
nificantly altered were used in the comparison. From the study reported
in Seyfried et al., 2017, the results from dorsolateral prefrontal cortex
were selected for verification, and proteins fulfilling the following cri-
teria were considered as DEPs: ANOVA with post-hoc Tukey's HSD test
p-value< 0.05. For the comparison, the highest log2 fold change values
were used in case of all DEPs.
3. Results
3.1. Human brain proteome profiling
We employed a mass spectrometry-based approach to interrogate
the human brain proteome during AD progression (B/B stages) in four
distinct brain regions: entorhinal cortex (EC), parahippocampal cortex
(PHC), temporal cortex (TC) and frontal cortex (FC). Importantly, we
wanted to evaluate brain areas that are affected by tau pathology at
different disease stages, in order to gain insights if there are common
mechanisms or patterns shared between different brain regions during
disease progression. Among the investigated regions EC and PHC that
belong to the medial temporal lobe are affected already at the early,
while the neocortical regions (TC, FC) are affected by tau pathology
only at the late stages of AD (Braak and Braak, 1991). A total of 103
samples were analyzed individually, furthermore, digestion replicates
were generated for each brain region in order to evaluate the re-
producibility of sample preparation. As expected, the correlation was
higher between digestion replicates than biological replicates from the
same disease group (Fig. S2). In total 3809, 3815, 3610 and 3720
protein groups with at least 2 peptides were identified in EC, PHC, TC,
and FC, respectively. There was a large overlap (> 85%) between the
identified protein groups from different disease stages in each brain
region as it is indicated in Fig. S3. Gene ontology enrichment for cel-
lular components (GOCC) revealed similar categories for the four brain
regions (Fig. S4).
Comparative proteome profiling during disease progression
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Fig. 1. Graphical illustration of the study design.
Two approaches were employed in the study: 1) comparative proteome profiling during disease progression to unravel altered proteins/pathways in different brain
regions and 2) comparative proteome profiling of different brain regions in healthy subjects to investigate brain region vulnerability to AD.
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3.2. Proteins differentially expressed during AD progression
In this work, we employed two approaches to analyze differences in
proteome profiles of brain areas affected by tau in early (EC, PHC) and
late disease stages (TC, FC) (Fig. 1). Firstly, in order to understand how
the brain proteome is altered during AD progression, we investigated
which proteins are differentially expressed when comparing early (B/B
I-III) and late disease stages (B/B IV-VI) to control individuals in each
brain region. Secondly, to investigate physiological proteomic sig-
natures that might contribute to brain area susceptibility to AD, we
compared the proteomic profiles of the four brain regions in healthy
subjects (controls).
Regarding the first approach (investigation of changes in the pro-
teome of each region during AD progression), a total of 248, 278, 163
and 171 proteins were significantly different in EC, PHC, TC, and FC,
respectively, totalizing 737 proteins (Table S3). Interestingly, the
highest numbers of DEPs were observed in the regions affected early by
tau pathology. Early changes in protein levels were observed in each
region but the number of altered proteins increased when the late
disease stage was compared with controls (Fig. S5). The comparison of
DEPs from various brain regions revealed that there is only a small
overlap between regions, especially during the early stages, although
there is an increase in the number of shared proteins during the late
stages. The comparison of differentially expressed proteins found in
each region indicated that in total 101 proteins are shared between two,
and only 11 proteins are shared between three brain regions (Table 1,
Fig. S6). Out of these 112 proteins, 99 showed similar expression level
changes across brain regions (up- or down-regulated in all comparisons)
and only 13 changed in opposite directions across comparisons (up-
regulated in one and down-regulated in another brain region). Some of
the aforementioned 11 proteins are involved in metabolic processes
(CTNND1, FLNA, AUH, RNPEP, and NUMBL) and related to cell-ad-
hesion: CTNND1, FLNA and NUMBL play a role in adherens junction
organization; and CTNND1, FLNA and SH3GL1 are expressed in the cell
junction. Hierarchical clustering of the 11 proteins altered in three
brain regions was performed and a heat map was generated considering
their expression during disease progression in all brain areas (Fig. 2A).
Two main protein clusters were detached with opposite expression
profiles during disease progression, in addition to Bcl-2-like protein 13
(BCL2L13) that was down-regulated in MTL but slightly up-regulated in
the neocortex. The cluster with augmented expression levels in late
disease stages consists of 3 proteins including two well-known AD
players: filamin A (FLNA) and glial fibrillary acidic protein (GFAP), a
marker of astrocytes, while the other cluster of 7 proteins shows re-
duced levels in AD compared to controls.
We wondered if some proteins that were found to be altered during
disease progression have already been associated with genetic risk for
AD. A comparison was done between all 737 differentially expressed
proteins and a list of AD risk genes published recently (Hu et al., 2017).
We found that 27 proteins have already been described as AD risk loci
(Fig. 2B). With the aim to better clarify the relationship between these
proteins, an interactome showing protein-protein interactions was built
with String (Fig. 2C). The majority of proteins are connected, and APP
appears as a central node with the highest number of interactions.
Functional enrichment analysis revealed that synaptic proteins and
proteins involved in oxidative phosphorylation are overrepresented.
Additionally, some of these proteins are involved in pathways related to
neurodegenerative disorders, such as Alzheimer's disease (APP,
GRIN2B, GSK3β, MT-ATP8, MT-CYB), Parkinson's disease (MT-ATP8,
MT-CYB, MT-ND1, MT-ND4) and Huntington's disease (GRIN2B, MT-
ATP8, MT-CYB, TFAM).
3.3. Altered pathways during AD progression
In order to evaluate segregation of disease stages and to observe
expression profiles, hierarchical clustering of DEPs from the four brain
regions (EC, PHC, TC, and FC) was performed. Four major protein
clusters were found, which represent distinct expression patterns (early-
up, early-down, late-up and late-down) during disease progression. The
majority of altered proteins were found down-regulated in AD con-
sidering all regions (> 70% in MTL and > 60% in the neocortex)
(Figs. 3 and 4). With the aim to clarify which pathways and processes
are altered during disease progression, each cluster was further sub-
jected to enrichment analysis.
Regarding EC, pathway analysis revealed that the mitochondrial
respiratory chain complex I assembly is significantly enriched in the
early-down cluster that consists of 14 proteins, indicating an impair-
ment in oxidative phosphorylation. The late-down cluster incorporates
189 proteins, among which proteins involved in vesicle-mediated and
protein transport, translation including ribosome subunits, as well as
synaptic proteins are highly enriched. A greater impairment in oxida-
tive phosphorylation was also observed in this cluster. On the other
hand, the early-up cluster presents 24 proteins, some of which are as-
sociated with cell-cell adhesion. 21 proteins belong to the late-up
cluster, where cell adhesion and astrocyte development were found as
enriched processes (Fig. 3 and Table S4).
Considering PHC, 104 proteins are present in the early-down
cluster, and as it was seen in EC oxidative phosphorylation is sig-
nificantly enriched. Actin filament and synapse-based processes are also
present in this cluster. PHC late-down cluster is composed of 95 pro-
teins, which are related to oxidative phosphorylation, translation, and
synapse. Interestingly, these processes were also found in EC late-down
cluster. PHC early-up cluster harbors 26 proteins, which are related to
platelet aggregation and the regulation of cell shape. The late-up cluster
has 39 proteins that are associated with extracellular matrix organiza-
tion, cell adhesion and UDP-N-acetylglucosamine biosynthetic process
(Fig. 3 and Table S4). Remarkably, proteins involved in cell adhesion
were also present in EC early-up and late-up clusters.
Considering TC, the early-down cluster has 48 proteins that are
mainly involved in synaptic processes and oxidative phosphorylation
(respiratory electron transport chain). The late-down cluster presents
48 proteins that are related to cell adhesion and to the regulation of
cytoskeleton organization. The early-up cluster consists of 62 proteins
that are associated with the oxidation-reduction process, cholesterol
metabolic processes and lipid transport. Only 5 proteins compose TC
late-up cluster, where extracellular matrix organization is one of the
few processes found enriched (Fig. 4 and Table S5).
Concerning FC, the early-down cluster contains 31 proteins, which
are mainly synaptic proteins. In total, 61 proteins form the late-down
cluster of FC, where synapse and protein translation were found en-
riched. FC early-up cluster presents 33 proteins, which are related to
acute phase response and platelet activation. Finally, FC late-up cluster
includes 26 proteins that are involved in extracellular matrix organi-
zation (Fig. 4 and Table S5).
Up and down-regulated proteins in each brain region were sub-
mitted to enrichment analysis for cellular component categories
(GOCC) to unravel key cellular parts/organelles affected by the disease.
This analysis revealed a remarkable down-regulation of the
Fig. 2. Proteins differentially expressed during AD progression.
A) Hierarchical clustering of 11 proteins that are altered in 3 brain regions. Cluster in red: up-regulated proteins during AD course; Cluster in green: down-regulated
proteins during AD course. B) Venn diagram showing the overlap of AD risk loci with DEPs found in each brain region. C) Protein interactome of DEPs described as
AD risk genes. Line color indicates the type of interaction evidence (yellow: textmining, purple: experiments, light blue: databases, black: co-expression, blue: co-
occurrence). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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Table 1
Differentially expressed protein (DEPs) during AD progression that are shared between brain regions
represented by their log2 fold changes. Red color indicates up-regulated, blue color indicates down-
regulated proteins in AD.
Gene name 
Early B/B stages Late B/B stages 
EC PHC TC FC EC PHC TC FC 
GFAP 0.771     0.893 1.212 0.914   0.884 
FLNA 1.286 0.911   1.369 0.949 1.008     
AUH       -0.834 -0.717 -0.684     
CEP170B         -1.123   -0.679 -0.636 
CTNND1       -0.858 -1.568   -1.144   
BCL2L13     1.393   -2.675 -1.461 1.267   
RNPEP 1.153         0.845   0.837 
RFTN1 0.652           -1.019 -0.842 
SH3GL1           -0.836 -0.845 -0.840 
STRN4           -0.879 -0.901 -0.665 
NUMBL   -0.754       -1.446 -0.810 -0.991 
CAPS   2.360     3.166 3.171     
ANXA1   1.475     1.801 1.964     
PLIN3         1.462 1.093     
BDH2         0.954 0.771     
RAB33B   -1.018     -0.606 -0.917     
MT-ND4         -0.632 -0.834     
RAP2A   -0.786     -0.647       
THY1         -0.681 -0.723     
RAB3GAP1         -0.683   -1.360   
GAP43         -0.751 -0.642     
FXYD7         -0.772 -1.828     
PCCB         -0.805 -0.700     
SYT7         -0.866 -0.868     
DIRAS2 -0.606       -0.886 -0.868     
HPCA         -0.901 -1.009     
PLXNA1       -1.301 -0.908     -1.369 
RPTOR       -1.864 -0.949       
ESYT1         -0.972   0.675   
MARK2     -0.911   -0.995   -0.830   
GMPS         -1.021 -1.262     
LRRC57 -0.638       -1.058 -0.708     
RPS13         -1.135 -1.341     
SRC   -1.167     -1.192       
SCN2A         -1.210     -0.590 
EMC1 -0.879       -1.238     -0.812 
FGF12   -0.927     -1.249 -0.614     
ATPAF1 -1.188       -1.281 -1.472     
UQCR10         -1.326 -0.607     
DIRAS1         -1.372   1.171   
VAMP2         -1.377 -0.684     
C2CD4C         -1.412     -1.571 
GGA3         -1.412     1.016 
SLC25A46         -1.414 -2.197     
AP3M2         -1.590 -1.647     
RAB10       -1.141 -1.684       
CA4       -0.755 -1.770     -1.141 
IGSF21         -1.781     -0.812 
SCYL1     -2.280   -2.437       
KYAT3 1.405 0.862             
RPA3 1.370     -0.858         
GNG5 1.103   2.394           
CLIC1 0.948         1.083     
CAPG 0.826     0.761         
GYG1 0.685           0.628   
(continued on next page)
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Table 1 (continued)
DYNLL2 -0.630 -0.688       -1.149     
SDHC -0.711         -1.596     
TRIM3 -1.060   -0.652           
CHN1 -1.301   -0.794           
EXOC7 -1.905 -2.113       -2.009     
DLGAP1     -1.136     -0.705     
ERC2           -1.588 -1.146   
PFDN6       -1.484   -1.377     
VGF           -1.890   -2.014 
EXOC3       -0.778   -1.339     
PFKFB2       0.991   1.122     
ORM1       1.286     0.883 1.590 
ALB           0.709   0.604 
APP           1.447 0.843   
CD63   -1.245       -0.683   -0.608 
MAP2     -0.926     -0.799 -0.586   
VCAN           0.847   0.805 
ACYP2     -0.727     -0.795     
COX6B1     -1.084     -0.808     
GABRA1           -0.907 0.980   
CD44           2.354   1.362 
RAB3B             -0.888 -1.126 
GART       0.619   1.012     
FDXR     1.477     -1.182     
PIK3R1           -0.932 -0.775   
CORO1A           -0.614 -0.666   
SPR   0.687         0.984   
KRT2     2.237     -2.021     
AGFG1           -0.743 -0.630   
SUB1       -1.585   -1.767     
RPL23A     -1.088         -0.867 
RPL23 -0.952 1.094
FKBP1A -0.859 -0.890
GRIN1 -1.196 -1.017
TARDBP -0.582 0.818
GRIN2B -1.443 -0.708
SCARB2 1.447 1.128 1.473
CTTN -0.858 -1.159
CAMK4 -0.587 -0.625
KIAA1217 -1.347 -1.567
SLC27A4 -0.761 -0.946
SH2D5 -1.312 -1.177 -1.097
RIMS1 -0.738 -0.842 -0.863
HOMER1 -0.852 -0.668
DMXL2 -0.856 -0.693
SCFD1 -0.621 -0.905 0.711
NRGN -1.056 -0.820 -1.152
ACSF2 -1.048 -1.014
EXOC2 -0.599 0.846
SYNGAP1 -0.642 -0.618
SGIP1 -1.015 -0.628
RAB11FIP5 -1.105 -1.037 -1.640
PHACTR1 -0.969 -0.956
HAPLN2 0.754 1.112
TANC2 -0.626 -0.888
BSN -0.669 -0.814
PCLO -1.604 -0.788
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mitochondrial and ribosomal proteins in MTL regions. In addition, a
global down-regulation of synaptic, dendritic and axonal proteins oc-
curred in all 4 regions (Fig. 5A). Mitochondrial oxidative phosphor-
ylation impairment and translation dysregulation were evident pri-
marily in the two MTL regions, however, a few related proteins were
found altered in the neocortex as well (Table S4 and Table S5). Proteins
associated with oxidative phosphorylation and translation pre-
dominantly show a decreasing expression profile in MTL during disease
progression. On the contrary, in neocortex the majority of these pro-
teins are unaffected, and only a few proteins were found significantly
down-regulated in AD (Figs. 5B and C).
3.4. Proteome profiling of healthy subjects in different brain regions
Currently, the matter of brain area vulnerability in neurodegen-
erative disorders is a highly debated and unsolved question. Our goal
was to identify distinctive proteomic signatures in the brain that can be
associated with the susceptibility of some areas to present early de-
generation in AD. The comparison of the proteome from healthy in-
dividuals (controls) resulted in 648 differentially expressed proteins
between the four brain areas (Table S6). Hierarchical clustering of all
648 DEPs was performed and the resulting dendrogram clearly sepa-
rated MTL samples from neocortical samples (Fig. 6A). DEPs were di-
vided into 2 major clusters: one group of 238 proteins with higher levels
in the neocortex compared to MTL (MTL-down) and another group of
410 proteins that are more expressed in MTL (MTL-up).
In order to clarify which pathways are more active in specific brain
areas, each cluster was subjected to enrichment analysis using DAVID
(Table S7). It is noteworthy that several overrepresented pathways in
the MTL-up cluster have already known link to AD, such as energy
production (oxidative phosphorylation), protein translation, protea-
some (Fig. 6B). Long-term potentiation is also significantly enriched in
this cluster. A total of 16 ribosomal proteins (RPL17, RPL27A, RPL36,
RPL38, RPS4X, RPS16, RPL23, RPL9, RPS14, RPS12, RPL10, RPL5,
RPS10, RPS20, RPS11, RPL4) and 10 proteins from proteasome-com-
plex (PSMA2, PSMD12, PSMC4, PSME1, PSMC2, PSMB3, PSMC1,
PSMB2, PSMD7, PSMD8) were found among the proteins significantly
upregulated in MTL. Additionally, a greater number of mitochondrial
proteins was recognized in cluster MTL-up (79 proteins, 19.27%)
compared to cluster MTL-down (24 proteins, 10.08%).
Regarding the cluster of proteins significantly up-regulated in the
neocortex, some proteins involved in proteasome regulation (negative
regulation of proteasomal ubiquitin-dependent protein catabolic pro-
cess (GO:0032435)), e.g. UBXN1, BAG6 and CCAR2 are enriched in this
cluster, but none of them belongs to the proteasome complex. Proteins
involved in mRNA splicing via spliceosome (HNRNPL, SRSF1, NONO,
SF3B1, SRSF7, ELAVL1, RBMX, YBX1) and in integrin-mediated sig-
naling pathway (ADAM23, LAMA5, SEMA7A, ADAM22, ZYX, DST) are
exclusively enriched in this cluster. Cytoskeleton and synapse-related
proteins are overrepresented in both clusters (Table S7).
We further investigated whether some of these proteins that dif-
ferentiate MTL and neocortex in healthy tissue were altered in AD as
well. Interestingly, 226 proteins (out of 648) showed altered levels
during disease progression. We found that proteins with higher ex-
pression level in MTL were almost exclusively down-regulated in the
same brain region during AD progression, and similar behavior was
observed in the neocortex, i.e. many proteins with higher abundance in
healthy neocortical tissue showed reduced expression in this brain re-
gion during disease.
3.5. Comparative analysis with other proteomic studies in AD
With the aim to confirm the validity of our findings, we sought to
compare our full dataset of dysregulated proteins during AD progres-
sion (737 proteins in the four brain regions) with the lists of altered
proteins reported by two recently published AD proteomic studies
(Hondius et al., 2016; Seyfried et al., 2017). In total, 275 proteins were
shared between at least two studies, and 24 proteins were dysregulated
in AD in all three studies (Fig. 7A; Table S8). The common proteins
showed similar behavior in all proteomic studies, 19 proteins (G3BP2,
ABI2, ACTR3B, TWF2, SV2B, SYNGAP1, ANKS1B, CORO1A, HPCA,
PCDH1, CAMK2A, ACTN2, TUBB3, PACSIN1, NCKAP1, SLC8A2,
FAM162A, GNAZ, GDAP1) were found down-regulated, while 5 (TLN1,
VIM, G6PD, GFAP, PLCD1) were up-regulated in AD. (Table S8, high-
lighted). This is especially interesting since the previous works focused
on different brain regions, e.G. hippocampus (Hondius et al., 2016) and
dorsolateral prefrontal cortex (Seyfried et al., 2017).
To unravel the role of the conserved proteins, functional enrichment
analysis was carried out using proteins shared between at least two
studies. Only concordant proteins (changes in their expression levels
show the same direction in all studies) were evaluated in this analysis.
Among up-regulated proteins, the most significant biological process
categories were extracellular matrix organization, cell adhesion, lipid
metabolic processes, platelet degranulation and astrocyte development
(Fig. 7B). On the other hand, down-regulated proteins are mainly in-
volved in microtubule-based processes, vesicle-mediated transport, and
synaptic vesicle endocytosis, ephrin receptor signaling, and cytoske-
leton organization (Fig. 7B).
Remarkably, 195 proteins that showed alteration during AD in the
present study have already been described previously. Additionally, the
majority of these proteins (166) shows similar expression level changes
to what previously reported (Table S8). With the aim to better assess
the similarity between our results and other proteomic studies, we
compared the log2 fold changes of overlapping altered proteins
(Fig. 7C). Moderate correlation (R2) was found between our results and
the datasets from Hondius et al. and Seyfried et al. that comprised brain
regions similar to those investigated in the current study. It is important
to note that, although there are differences between the log2 fold
changes of various proteins, which has an impact on the correlation, the
great majority of common proteins show accordant changes across the
studies. Overall, these results reinforce the validity of our proteomic
findings.
3.6. Verification of a set of differentially expressed proteins by targeted MS/
MS
To confirm the validity of our label-free quantification approach a
set of differentially expressed proteins from the discovery phase were
selected for PRM analysis. 75 peptides corresponding to 21 proteins
were included and successfully detected in the final PRM assay panel.
By comparing controls with the AD groups 16 proteins out of the 17
DEPs showed significant differences in at least one brain region, fur-
thermore, expression level alterations between the MTL and neocortical
regions were confirmed for 5 proteins including APOE (Table S9,
Fig. 8A and B). In addition to determining APOE level with the help of
the isoform-specific SIS peptides we were able to identify APOE phe-
notypes as well, as we described it in our previous publication (Rezeli
et al., 2015). We found all six different phenotypes among the samples,
but we couldn't make a systematic quantitative comparison between
phenotypes since> 70% of the samples were ε3 homozygotes (Table
S1).
In contrast to the discovery phase during PRM analysis Aβ level was
measured separately from APP by using a peptide (LVFFAEDVGSNK),
corresponding to residues 17–28 of Aβ. Although this peptide is not
suitable for differentiating between the holoprotein and its fragment,
the different behavior of the Aβ peptide and the other APP peptides
indicates that it is appropriate for measuring Aβ levels. Significant in-
crease in the Aβ level was observed in each region during AD pro-
gression, while APP was constant or slightly decreased (Fig. 8C).
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Fig. 3. Hierarchical clustering and functional enrichment analysis of DEPs in the MTL during AD progression.
Heat maps built with DEPs found in EC and PHC. Clusters representing the four typical expression profiles are colored accordingly to the heat maps. The 5 most
significant biological processes (GOBP) are listed for each expression profile.
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Fig. 4. Hierarchical clustering and functional enrichment analysis of DEPs in the neocortex during AD progression.
Heat maps built with DEPs found in TC and FC. Clusters representing the four typical expression profiles are colored accordingly to the heat maps. The 5 most
significant biological processes (GOBP) are listed for each expression profile.
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Fig. 5. Key cellular parts/organelles and pathways affected by AD.
A) Representative cellular component categories (GOCC) in down-regulated protein clusters. B) Expression profiles of proteins related to oxidative phosphorylation.
C) Expression profiles of proteins involved in translation.
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Fig. 6. Hierarchical clustering and KEGG pathway analysis of DEPs between brain regions in healthy subjects.
A) Heat map built with DEPs between brain regions. B) Top 15 KEGG pathways enriched for proteins up-regulated in MTL.
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Fig. 7. Comparison of the altered proteins with independent AD proteomic datasets.
A) Venn diagram showing the overlap of DEPs between the present work and two other proteomic studies. B) Gene ontology (GOBP) enrichment analysis for
overlapping proteins between at least two proteomic datasets (n= 275). C) Log2 fold changes of shared proteins between the current work and two other proteomic
studies; the general correlation is shown (R2).
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4. Discussion
4.1. Proteomic changes during AD progression show a complex scenario
with a few shared but mostly specific processes in the different brain regions
We observed 112 dysregulated proteins and a few pathways during
AD course that are shared between 2 or more brain regions, possibly
indicating their importance in the pathogenesis of the disease.
Strikingly, the great majority of these proteins shows concordant
changes in their expression levels in AD, further reinforcing the ex-
istence of common key processes in distinct brain regions (Table 1).
Many proteins, however, were exclusively dysregulated in specific
brain areas and the majority of altered pathways during the disease
course was specific to certain brain regions. Regarding the progress of
the disease, the similarities and differences found between the in-
dividual brain regions are most likely linked to the high degree of
specialization of the brain. In accordance with the endogenous speci-
ficities of various brain areas, we hypothesize that genetic and en-
vironmental triggers of AD affect individual brain regions differentially,
and this is reflected in the found diversity of dysregulated protein ex-
pression. In other words, we assume that the regionally different re-
sponses to early AD triggers are the consequences of the different
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Fig. 8. Verification of a set of differentially expressed proteins by PRM.
A) Box-plot representing GFAP and CORO1A expression levels in EC and TC, respectively. B) Box-plot representing total APOE and CD63 expression levels of control
subjects in 4 different brain regions. C) Box-plot representing ABETA and APP expressions in 4 different brain regions during AD progression.
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proteomic background of each region. In some regions, proteomic
changes may already be observed independent of the presence of classic
pathological features of AD (e.g. tau protein aggregation). For instance,
changes of the proteome in neocortical areas were observed in early B/
B stages, suggesting that these regions have already responded to AD
triggers regardless of tau seeding. According to our proteomic data
synapse loss occurred in all analyzed regions, indicating that this pro-
cess is ubiquitous in AD.
4.2. Synapse loss, translation dysregulation, and oxidative phosphorylation
impairment during AD progression and their implications to disease
Processes associated with synapse were found down-regulated in AD
in all four brain areas (Fig. 5A). Synapse loss is a pathological hallmark
of AD and it is an early event in disease, occurring before neuron death
(Scheff et al., 2006). Synaptic degeneration presents the best correla-
tion with cognitive impairment, even higher than NFT or Aβ plaques
deposition (Terry et al., 1991). The alteration of synaptic proteins was
observed in both neocortical regions during early B/B stages (Table S5),
which suggests that earlier events, occurring before the accumulation of
insoluble tau tangles, trigger neuron dysfunction. This is supported by
previous studies, which reported that synapse loss occurs before tangles
formation in a tauopathy mouse model (Yoshiyama et al., 2007) and
soluble tau causes synaptic dysfunction in an early AD model (Polydoro
et al., 2013). Additionally, Aβ peptide has also been shown to cause
synaptic degeneration (Walsh et al., 2002).
Several proteins involved in translation were found down-regulated
in AD, mostly in 3 regions (EC, PHC, and FC). In total, 18 ribosomal
subunits and 4 translation initiation factors showed reduced levels in
these regions, however, in TC, only 3 proteins associated with trans-
lation were altered (1 down- and 2 up-regulated in AD) (Table S10).
Some of the translation regulators were altered already in early B/B
stages in neocortical regions, indicating dysregulated pathways before
insoluble tau deposition. In line with our findings, several studies re-
ported altered protein synthesis and ribosomal protein expression in
various brain regions from AD patients (Ding, 2005; Garcia-Esparcia
et al., 2017; Hernández-Ortega et al., 2015). Previous research identi-
fied a high number of translation machinery members among Aβ oli-
gomers interacting partners (Virok et al., 2011), and it was found that
tau interactome is enriched for proteins involved in translation and
RNA processing (Gunawardana et al., 2015). Furthermore, it was re-
ported that tau isolated from AD patients binds to more ribosomal
proteins than tau from control subjects, and tau oligomers inhibit
translation process (Meier et al., 2016). Table S10 summarizes the 24
dysregulated translation proteins in our AD cohort, associating our
findings with literature data.
Reduced levels of proteins associated to oxidative phosphorylation
were observed during early B/B stages in both MTL regions, with a
higher number of proteins being affected during late stages (Fig. 5B,
Table S4). In both EC and PHC, subunits of all electron transport chain
complexes (I-V) were down-regulated. Additionally, several mitochon-
drial proteins were down-regulated in the two MTL regions (Fig. 5A). In
contrast, in neocortical regions, only 4 proteins linked to oxidative
phosphorylation were down-regulated (NDUFS6, COX6B1, and MT-
ATP8 in TC, and NDUFA6 in FC). Hypometabolism is a known feature
of AD brains, occurring years before the onset of symptoms in AD-
vulnerable regions (de Leon et al., 2001; Mosconi et al., 2008). Previous
studies with human tissue and animal models showed that proteins
involved in energy generation in mitochondria, including mitochon-
drial electron transport chain subunits, are dysregulated in AD (Liang
et al., 2008; Shevchenko et al., 2012). Finally, a complex regulatory
mechanism underlies metabolism control, Aβ, and tau. Aβ and tau have
been implicated in the impairment of oxidative phosphorylation (Rhein
et al., 2009) and it was reported that APP is able to inhibit oxidative
phosphorylation independently of Aβ peptide (Lopez Sanchez et al.,
2017). Animal studies have demonstrated that tau has a new
physiological function in insulin signaling regulation (Marciniak et al.,
2017) and that energy deprivation increases the translation of BACE1,
resulting in higher Aβ levels (O'Connor et al., 2008). Furthermore that
glucose deficit induces tau phosphorylation and aggregation in a
tauopathy mouse model (Lauretti et al., 2017).
4.3. Relationships of AD-related differentially expressed proteins to other
diseases
Because it is rather difficult to find non-demented elderly controls
without tau pathology, our groups were not fully balanced with respect
to age. To overcome this issue, we removed all proteins significantly
associated with age from the list of differentially expressed proteins.
Investigating the set of age-associated proteins we found that our
findings were consistent with a previous report (McKetney et al., 2019),
as a little overlap was presented between regions, and a large propor-
tion of these age-related proteins was associated with extracellular
exosome (p-value=6.2e-86) and membrane (p-value=8.9e-29).
Furthermore, in order to examine what diseases could be related to
the proteins differentially expressed between AD and controls (DEPs),
Ingenuity analysis was performed. It allowed elucidating disease an-
notations significantly overrepresented among the DEP sets (Fig. S7).
Interestingly, in very few cases the same disease annotations were
overrepresented among DEPs for different brain regions (e.g. Seizures).
Notably, for late disease stages and the FC region, overrepresented
diseases included cancer, cardiovascular disease, and neurological dis-
orders (e.g. epilepsy, brain neurodegeneration). For late B/B stages and
the PHC region, most of the overrepresented disease annotations re-
lated to neuropsychiatric disorders (e.g. epilepsy, neuromuscular dis-
ease, schizophrenia), while in the TC region, inflammatory diseases
were noteworthy. The sets of DEPs for early B/B stages were much
smaller than those for late stages, consequently, fewer disease annota-
tions were overrepresented (Table S11). Among these, pervasive de-
velopmental disorder (EC region) stood out.
The complex relationship between AD and other diseases is far from
being fully understood as can be exemplified by the 86 differentially
expressed proteins related also to melanoma according to the Ingenuity
database (Fig. S8). This protein set includes both down- and upregu-
lated proteins from various subcellular compartments, among them
regulators such as CUL1 and CD44.
4.4. The vulnerability of brain areas to AD
An intriguing question in AD and other neurodegenerative disorders
is why do some brain regions accumulate toxic protein aggregates and
degenerate first. To gain potential insights into this, we analyzed pro-
teomic differences between EC, PHC, TC, and FC in healthy control
subjects.
Hierarchical clustering resulted in clear segregation of MTL and
neocortical samples (Fig. 6A) that is consistent with the anatomical and
functional differences of these regions. The MTL is involved primarily in
memory functions (Squire et al., 2004), while the neocortex is rather
related to cognitive processes (Rakic, 2009). MTL has high energy de-
mands due to increased synaptic plasticity (memory formation and
storage) and the presence of large neurons (Mosconi, 2013), which is in
line with our results that metabolism-related pathways (metabolic
pathways, oxidative phosphorylation, insulin signaling) and mi-
tochondrial proteins were highly overrepresented in the cluster of
proteins with augmented levels in MTL. Translation and proteasome
pathways were also significantly enriched in MTL, indicating an ac-
celerated proteostasis; as well as long-term potentiation that is con-
sistent with EC and PHC involvement in memory formation (Fig. 6B).
Interestingly, Alzheimer's disease KEGG pathway was also found en-
riched in the cluster of proteins overexpressed in MTL (22 proteins, p-
value= 1.61e-7).
Remarkably, one of these AD proteins was APOE, the major genetic
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risk factor for late-onset AD (Corder et al., 1993). We found that APOE
level is generally higher in MTL compared to the neocortex, however,
statistically significant differences were observed only between PHC
and TC in the discovery dataset, as well as between both MTL regions
and FC in the PRM dataset (Table S6, Fig. 8B). A previous work re-
porting that APOE mRNA level is augmented in EC compared to other
brain areas (Liang et al., 2007) also strengthens our assumption that the
MTL expresses APOE in higher level. Nevertheless, further studies are
required to confirm the link between increased APOE level and AD
vulnerability.
Recent studies elucidated the missing link between APOE, Aβ and
tau, since it has been shown that APOE ε4 allele mediates and exacer-
bates tau toxic effects (Shi et al., 2017) and APOE mediates APP tran-
scriptional regulation in such a way that APOE ε4 presenting the highest
induction of APP expression and APOE ε2 the lowest (Huang et al.,
2017). Accordingly, APOE ε4 represents an increased risk for AD, while
APOE ε2 is protective against AD (Yu et al., 2014). APOE plays a role in
metabolism regulation and it is known that its isoforms differently
regulate glucose pathways (Keeney et al., 2015). It has been previously
shown that APOE ε4 decreases the levels of mitochondrial respiratory
complexes, further linking APOE to mitochondrial metabolism (Chen
et al., 2011). In addition, APOE has transcriptional factor activity as it
binds to the promoter of genes related to trophic support, programmed
cell death, microtubule disassembly, synaptic function, aging, and in-
sulin resistance (Theendakara et al., 2016).
Considering the increased APOE level in MTL, the relevance of
metabolic control in this region, as well as the relationship between
APOE, Aβ, and tau, we summarize how differences in APOE expression
could be related to MTL vulnerability to AD (Fig. 9). We believe that 1)
the proteomic background, including higher APOE level together with
2) the high energy demand of MTL, impaired early in AD, make this
region more susceptible to early triggers of AD. Previous work de-
scribed the correlation between AD histopathological staging and the
expression pattern of proteins that co-aggregate with plaques and tan-
gles, as well as proteins involved in Aβ and tau homeostasis (Freer
et al., 2016). These observations collectively suggest that a sum of
factors might account for brain region vulnerability to AD and the
whole picture needs to be elucidated.
4.5. Comparison of proteomic studies in AD reveals overlapping proteins
and pathways
A recent review of proteomic studies in AD reported low reprodu-
cibility between distinct works (Moya-Alvarado et al., 2016). However,
we compared our results with two other proteomic datasets reported
earlier, and 275 overlapping DEPs between at least two studies were
found, furthermore, 85% of the common proteins showed concordant
expression level changes across studies. The low number of overlapping
proteins (24) between the three studies might be due to the anatomical
divergence between the analyzed brain regions. Taken together, these
results indicate that there is a certain degree of overlap between various
proteomic studies, and most probably, the intersection denotes im-
portant proteins to AD pathology. A recent work that compared the
results from three transcriptomic studies on the human hippocampus in
AD (Hargis and Blalock, 2017), revealed that the overlapping up- and
down-regulated genes are involved mainly in cell adhesion and platelet
aggregation, and in energy metabolism and synaptic processes, re-
spectively. This is in great agreement with the enrichment analysis
results we got for the overlapping proteins between proteomic studies
in AD (Fig. 7B). This further strengthens the view that there are key
proteins and pathways commonly identified by distinct transcriptomic/
proteomic studies which are of importance to AD etiology.
5. Conclusions
This work provides a description of the proteomic changes during
AD progression in brain regions early and late affected by tau pa-
thology. We identified peculiar mechanisms to each region during AD
progression, but also found processes that are shared between regions
possibly representing fundamental features involved in disease
etiology. Based on the different proteomic signatures of MTL and neo-
cortex, we contextualized brain region vulnerability to AD with the
current Aβ/tau paradigm. In summary, this work provides insights into
how distinct brain regions behave in health and during the course of
AD. The results found strengthen the view that the differential pro-
teomic background of various brain areas might be related to their
implication in AD. In addition, we reinforce that the series of events
leading to AD should be investigated at the whole brain level since the
inherent characteristics of each brain region might be related to specific
molecular alterations during disease. Future studies spanning more
areas are needed to better clarify the cascade of events involved in AD
and why particular brain regions are affected first by certain neurode-
generative diseases.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nbd.2019.104509.
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